scispace - formally typeset
Y

Yan Deng

Researcher at Huazhong University of Science and Technology

Publications -  24
Citations -  3272

Yan Deng is an academic researcher from Huazhong University of Science and Technology. The author has contributed to research in topics: Intermittent hypoxia & Oxidative stress. The author has an hindex of 11, co-authored 20 publications receiving 2651 citations.

Papers
More filters
Journal ArticleDOI

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province.

TL;DR: The majority of patients with 2019-nCoV pneumonia present with fever as the first symptom, and most of them still showed typical manifestations of viral pneumonia on chest imaging, suggesting middle-aged and elderly patients with underlying comorbidities are susceptible to respiratory failure and may have a poorer prognosis.
Journal ArticleDOI

Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease.

TL;DR: Investigation of the factors affecting the progression of pneumonia in COVID-19 patients in Wuhan aimed to investigate the risk factors for disease progression and find the optimal treatment regimens for CO VID-19 pneumonia.
Journal ArticleDOI

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study.

TL;DR: A retrospective investigation was conducted to analyze the clinical characteristics of fatal cases of COVID-19 patients who succumbed to and who recovered from 2019 novel coronavirus disease and to compare them with recovered patients.
Journal ArticleDOI

Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia

TL;DR: The increased expression of IL-2R and IL-6 in serum is expected to predict the severity of the 2019-nCoV pneumonia and the prognosis of patients.
Journal ArticleDOI

Atorvastatin attenuates myocardial remodeling induced by chronic intermittent hypoxia in rats: Partly involvement of TLR-4/MYD88 pathway

TL;DR: Pre-CIH atorvastatin administration may attenuate TLR-4/MYD88 mediated inflammatory processes and oxidative stress in the injured rat myocardium, and this may be one mechanism by which atorVastatin ameliorated myocardial injury following CIH.